What we have learned about antenatal corticosteroid regimens

被引：11

作者：

Wapner, Ronald J. ^{[1
]}

Gyamfi-Bannerman, Cynthia ^{[1
]}

Thom, Elizabeth A. ^{[2
]}

机构：

[1] Columbia Univ, Med Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA

[2] George Washington Univ, Ctr Biostat, Washington, DC USA

来源：

SEMINARS IN PERINATOLOGY | 2016年 / 40卷 / 05期

关键词：

Antenatal corticosteroids; Betamethasone; Preterm Birth; Respiratory distress; RESPIRATORY-DISTRESS-SYNDROME; BIRTH-WEIGHT INFANTS; MULTIPLE COURSES; PRETERM BIRTH; NEURODEVELOPMENTAL OUTCOMES; CONTROLLED-TRIAL; TERM OUTCOMES; SINGLE; DEXAMETHASONE; BETAMETHASONE;

D O I：

10.1053/j.semperi.2016.03.005

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Administration of antenatal corticosteroids has been standard of care for women between 24 and 34 weeks of gestation who are at risk for preterm delivery for more than 20 years longer in other parts of the world. Although the benefit of steroids in this population has been confirmed, there remain many questions including the frequency of dosing and whether it is possible to expand the gestational age criteria to women likely to deliver before 24 weeks or after 34 weeks. The MFMU Network has played a major role in answering some of these questions. (C) 2016 Elsevier Inc. All rights reserved.

引用

页码：291 / 297

页数：7

共 43 条

[21] SARS-CoV-2 infection and glucose homeostasis in pregnancy. What about antenatal corticosteroids?
Kakoulidis, Ioannis
Ilias, Ioannis
Koukkou, Eftychia
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (04) : 519 - 520
[22] What We Have Here is a Failure to Communicate: Obstacles to Optimal Care for Preterm Birth
Iams, Jay D.
Donovan, Edward F.
Rose, Barbara
Prasad, Mona
CLINICS IN PERINATOLOGY, 2011, 38 (03) : 517 - +
[23] Complications affecting preterm neonates from 1991 to 2006: what have we gained?
Groenendaal, F.
Termote, J. U. M.
van der Heide-Jalving, M.
van Haastert, I. C.
de Vries, L. S.
ACTA PAEDIATRICA, 2010, 99 (03) : 354 - 358
[24] What We Know and What We Do Not Know About Factors Associated with and Interventions to Promote Antiretroviral Adherence
Mannheimer, Sharon
Hirsch-Moverman, Yael
CURRENT INFECTIOUS DISEASE REPORTS, 2015, 17 (04)
[25] Pertussis: Where did we go wrong and what can we do about it?
Locht, Camille
JOURNAL OF INFECTION, 2016, 72 : S34 - S40
[26] Stroke in Malawi - What do we know about it and How should we manage it?
Mahawish, Karim M.
Heikinheimo, Terttu
MALAWI MEDICAL JOURNAL, 2010, 22 (01) : 24 - 28
[27] What Have We Learnt About the Treatment of Juvenile-Onset Systemic Lupus Erythematous Since Development of the SHARE Recommendations 2012?
Gallagher, Kathy L.
Patel, Pallavi
Beresford, Michael W.
Smith, Eve Mary Dorothy
FRONTIERS IN PEDIATRICS, 2022, 10
[28] What inpatient treatments do we have for acute intractable migraine?
Ali, Ashhar S.
Stillman, Mark
CLEVELAND CLINIC JOURNAL OF MEDICINE, 2018, 85 (07) : 514 - 516
[29] What do we know about DNA mechanics so far?
Aggarwal, Abhishek
Naskar, Supriyo
Sahoo, Anil Kumar
Mogurampelly, Santosh
Garai, Ashok
Maiti, Prabal K.
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2020, 64 : 42 - 50
[30] What Do We Know about Antimicrobial Activity of Astaxanthin and Fucoxanthin?
Karpinski, Tomasz M.
Ozarowski, Marcin
Alam, Rahat
Lochynska, Malgorzata
Stasiewicz, Mark
MARINE DRUGS, 2022, 20 (01)

← 1 2 3 4 5 →